Positive trial results for dexamethasone in treating COVID-19 patients have been welcomed by the off-patent industry as demonstrating the potential for repurposing existing generic medicines to help in the fight against the coronavirus pandemic.
With the World Health Organization citing the results from the UK’s “RECOVERY” – or Randomized Evaluation of COVID-19 Therapy – trial as demonstrating the anti-inflammatory drug to be “the first treatment to be shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support,” off-patent industry leaders have not only praised the